Enfuvirtide Intensification for Multi-Drug Resistant HIV |
United States |
Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment |
|
|
HIV Persistence after Successful CCR5-Depleted Stem Cell Transplantation |
United States |
HIV/AIDS |
|
|
HIV Controllers: A Potential Model for HIV Eradication |
United States |
HIV/AIDS, Immunology |
|
|
Impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease |
United States |
HIV/AIDS, Immunology |
|
|
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes |
United States |
HIV/AIDS |
|
|
Effects of CCR5 - delta-32 Heterozygosity on the HIV-1 Reservoir |
United States |
HIV/AIDS, Immunology, Genetics |
|
|
Validation of Existing Ultra-Sensitive Assays for Quantifying HIV Persistence |
United States |
HIV/AIDS, Drug and Diagnostics Development |
|
|
Atripla Adherence and Resistance Relationships [II] |
United States |
HIV/AIDS, Treatment Adherence |
|
|
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers |
United States |
HIV/AIDS, Drug and Diagnostics Development |
|
|
Atripla Adherence and Resistance Relationships [I] |
United States |
HIV/AIDS, Treatment Adherence |
|
|
Treating HIV-infected Elite Controllers as a Model of HIV Remission |
United States |
HIV/AIDS |
|
|
Epigenetic Regulation of HIV Latency |
United States |
HIV/AIDS |
|
|
Disulfiram to Accelerate Decay in HIV Reservoirs in ART Treated Patients |
United States |
HIV/AIDS |
|
|
Measuring the Latent reservoir for HIV |
United States |
HIV/AIDS, Drug and Diagnostics Development |
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START |
South Africa; Mali; Brazil; Peru |
HIV/AIDS, Drug and Diagnostics Development |
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) |
Tanzania; Zambia; Morocco; South Africa; Mali; Thailand; Greece; Argentina; Brazil; Chile; Peru |
HIV/AIDS |
|
|
San Francisco National Clinical Trial Center, ESPIRIT |
Morocco; Japan; Singapore; Thailand; Israel; Austria; Belgium; Denmark; France; Germany; Ireland; Italy; Netherlands; Norway; Poland; Portugal; Spain; United Kingdom; Argentina; Brazil; Canada; Australia |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Elite Controllers |
United States |
HIV/AIDS, Immunology, Genetics |
|
|
International Network for Strategic Initiatives in Global HIV Trials/ ICR INSIGHT |
South Africa; Mali; Brazil; Peru |
HIV/AIDS, Drug and Diagnostics Development |
|
|
Master Agreement: International Network for Strategic Initiatives in Global HIV Trials/ICR INSIGHT |
Uganda; South Africa; Mali; Nigeria; China; Malaysia; Thailand; Mexico; Argentina; Brazil; Chile; Peru; Uruguay |
HIV/AIDS |
|
|
Impact of Sex-Based Differences on HIV Reservoir Size and Immune Activation |
United States |
HIV/AIDS, Women's Health |
|
|
UCSF/Ragon Collaboration on HIV "Elite" Controllers |
United States |
HIV/AIDS, Drug and Diagnostics Development, Immunology, Genetics |
|
|
Preventing the Establishment of Enfuvirtide-Resistance in the Latent Reservoir |
United States |
HIV/AIDS |
|
|
Delaney AIDS Research Enterprise to Cure HIV |
United States |
HIV/AIDS, Drug and Diagnostics Development |
|
|
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation |
United States |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Therapeutic vaccination and PD-1 blockade in treated HIV disease |
United States |
HIV/AIDS |
|
|
DARE: Delaney AIDS Research Enterprise to Find a Cure |
Sweden; Australia |
HIV/AIDS |
|
|
T Regulatory Cells and T Cell Activation in HIV Disease |
United States |
HIV/AIDS, Immunology |
|
|
Treatment Intensification for Drug-Resistant HIV |
United States |
HIV/AIDS |
|
|
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation |
United States |
HIV/AIDS |
|
|
Impact of HIV-Associated Inflammation on Disease |
United States |
HIV/AIDS |
|
|
HIV Specific T-Cell Responses in Rectal Mucosa |
United States |
HIV/AIDS |
|
|
Characterizing the Role of Immune Activation in HIV Persistence |
United States |
HIV/AIDS, Immunology |
|
|
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen |
United States |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV |
United States |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Master Agreement: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS |
United States |
HIV/AIDS |
|
|
Deeks Order CNICS: June 2014-Aug 2016 |
United States |
HIV/AIDS |
|
|
Task Order: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS |
United States |
|
|
|
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response |
United States |
HIV/AIDS, Immunology |
|
|
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 |
United States |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Long Term Follow-Up of Patients Enrolled in Clinical Trials (#A-9602, A-9604, A-9801) Using Retroviral Gene Based Therapies / AIDS related research |
United States |
HIV/AIDS |
|
|
Core B: Specimen Repository Core |
United States |
|
|
|
Gender-specific Differences Affecting Reactivation of Latent HIV in Treated Patients |
United States |
HIV/AIDS, Immunology, Women's Health |
|
|
Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node |
United States |
HIV/AIDS |
|
|
Programming Long Term Durable HIV-1 Specific T cell Responses |
United States |
HIV/AIDS, Immunology |
|
|
HIV Entry Inhibitors: A New Therapeutic Option |
United States |
HIV/AIDS, Immunology |
|
|
Innate Effector Function and HIV-1 Control |
United States |
HIV/AIDS, Immunology |
|
|
EraMune Project |
United States |
|
|
|
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 |
United States |
HIV/AIDS, Noncommunicable and/or Chronic Disease, Pharmacology and Drug Treatment |
|
|
Identifying and Targeting HIV Persistence in T Cell Subsets during ART |
United States |
HIV/AIDS |
|
|
Identifying and targeting HIV persistence in T Cell subsets during ART |
United States |
Drug and Diagnostics Development, Immunology, Genetics |
|
|
Enhancing Control of HIV by Inhibiting TRAIL |
United States |
HIV/AIDS, Drug and Diagnostics Development, Immunology |
|
|
Short-Term Disulfiram Administration to Reverse Latent HIV Infection |
United States |
HIV/AIDS, Pharmacology and Drug Treatment |
|
|
Combination immune checkpoint blocker inhibition to eliminate HIV latency |
United States |
HIV/AIDS, Drug and Diagnostics Development |
|
|